Related Experiment Video
Updated: Mar 30, 2026
Delayed Intramyocardial Delivery of Stem Cells after Ischemia Reperfusion Injury in a Murine Model
Published on: September 3, 2020
Myocardial infarction: stem cell transplantation for cardiac regeneration
Edmund Carvalho1, Paul Verma2,3, Kerry Hourigan4
1IITB Monash Research Academy, Indian Institute of Technology Bombay, Mumbai, India.
Insights
Cardiovascular disease is a growing threat. Stem cell therapy shows promise for heart attack recovery, with ongoing research into cell types, delivery, and scaffold materials for better patient outcomes.
Area of Science:
- Regenerative Medicine
- Cardiovascular Research
- Biomedical Engineering
Background:
- Cardiovascular disease is a leading cause of mortality globally, with projections indicating a significant increase by 2030.
- Myocardial infarction (heart attack) remains a critical condition with limited effective regenerative treatments.
- Stem cell therapy offers a potential avenue for repairing heart tissue damaged by myocardial infarction.
Purpose of the Study:
- To review recent advancements in stem cell therapy for myocardial infarction.
- To analyze various cell sources, differentiation methods, and delivery techniques.
- To explore the role of scaffold matrices in enhancing stem cell engraftment and therapeutic efficacy.
Main Methods:
- Review of current literature on stem cell sources, including skeletal muscle cells, hematopoietic cells, mesenchymal stem cells (MSCs), embryonic stem cells (ESCs), and induced pluripotent cells (iPSCs).
- Analysis of cell differentiation protocols and expansion selection strategies.
- Evaluation of cell delivery methods and the impact of scaffold matrices on cell retention and survival.
- Assessment of the clinical translation status of stem cell-based therapies for myocardial infarction.
Main Results:
- Several stem cell types, including MSCs and ESCs-derived cardiomyocytes, have reached clinical trials.
- Induced pluripotent cells (iPSCs) are still in preclinical stages for myocardial infarction treatment.
- Effective cell delivery and retention at the injury site remain significant challenges.
- Scaffold matrices show potential in improving stem cell retention and promoting differentiation.
Conclusions:
- Stem cell therapy holds significant potential for treating myocardial infarction.
- Further research is needed to overcome challenges in cell delivery, retention, and clinical translation.
- Optimizing scaffold-based delivery systems is crucial for successful conjugate stem cell-based therapeutics.
Abstract:
It is estimated that by 2030, almost 23.6 million people will perish from cardiovascular disease, according to the WHO. The review discusses advances in stem cell therapy for myocardial infarction, including cell sources, methods of differentiation, expansion selection and their route of delivery. Skeletal muscle cells, hematopoietic cells and mesenchymal stem cells (MSCs) and embryonic stem cells (ESCs)-derived cardiomyocytes have advanced to the clinical stage, while induced pluripotent cells (iPSCs) are yet to be considered clinically. Delivery of cells to the sites of injury and their subsequent retention is a major issue. The development of supportive scaffold matrices to facilitate stem cell retention and differentiation are analyzed. The review outlines clinical translation of conjugate stem cell-based cellular therapeutics post-myocardial infarction.
Related Concept Videos
01:21Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
01:22iPS Cell Differentiation